UNSPSC 51392004: Sulfonterol

This classification denotes a beta-adrenergic agonist with the molecular formula C14H23NO4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Z540ZT2MI6, chemically known as benzenemethanol, alpha-(((1,1-dimethylethyl)amino)methyl)-4-hydroxy-3-((methylsulfonyl)methyl)- but generally known as sulfonterol, which bears US NIH Compound Identifier 170373. European Medicines Agency schedules Sulfonterol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10741MIG.

UNSPSC 51392004 Sulfonterol, a Commodity code, shows minimal recent state and local procurement activity aligned with its nominal pharmaceutical scope. The single recent opportunity posted under this code—Seminole County, Florida's IFB60459723LAS in June 2026—solicits naloxone and drug deactivation systems rather than sulfonterol, a long-acting beta-agonist bronchodilator. The mismatch suggests either a coding error in the county's procurement system or that this code is not the active vehicle for pharmaceutical procurement in state and local markets. The opportunity itself targets community health initiatives, with vendors required to supply 1,900 units of naloxone and 800 safe drug deactivation systems annually on a two-year initial term with one-year renewal option, delivered quarterly to the Seminole County Community Health Building in Sanford, Florida. Bidders must provide electronic submissions through the county's e-Procurement Portal, maintain workers' compensation and commercial general liability coverage, and comply with drug-free workplace and E-Verify requirements.

Geographic activity is limited to Florida based on the available record. Seminole County issued the sole recent posting, due July 26, 2023 (note: the posted date of June 30, 2026 appears inconsistent with the due date of July 26, 2023, suggesting a data-entry discrepancy in the source). The contract includes a three-month probationary termination clause and may draw FEMA funding, triggering compliance with the Clean Air Act and Federal Water Pollution Control Act. No explicit set-aside designations for disadvantaged enterprises are noted. Given the single posting and the divergence between the code's pharmaceutical name and the actual goods being solicited, this code does not appear to represent an active or reliable procurement vehicle for businesses targeting state and local pharmaceutical or drug-related product opportunities.